Svedberg, Anna <br/><br/>
Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.  [electronic resource] 

 -  British journal of clinical pharmacology  08 2019 
 - 1704-1709 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/bcp.13953  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cytochrome P-450 CYP3A--metabolism<br/>Drug Interactions<br/>Drug Monitoring--methods<br/>Erlotinib Hydrochloride--pharmacokinetics<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Quinine--administration & dosage<br/>Sex Factors